• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies.

作者信息

Oefelein M G, Smith N, Carter M, Dalton D, Schaeffer A

机构信息

Department of Urology, Northwestern University School of Medicine, Chicago, Illinois, USA.

出版信息

J Urol. 1995 Dec;154(6):2128-31.

PMID:7500474
Abstract

PURPOSE

Serum prostate specific antigen (PSA) has been reported to be a sensitive indicator of recurrent carcinoma after radical prostatectomy but it is not absolute. Disease progression with undetectable PSA levels has been described but the incidence of this phenomenon is unknown.

MATERIALS AND METHODS

We retrospectively analyzed the records of 394 consecutive men who underwent radical prostatectomy between 1980 and 1991 to characterize the incidence of recurrent carcinoma despite undetectable serum PSA levels.

RESULTS

Of the 394 men 133 had documented evidence of disease recurrence, 3 (2.3%) despite undetectable serum PSA levels (2 had local and systemic evidence of disease progression). Histological dedifferentiation characterized these recurrences.

CONCLUSIONS

Although a post-prostatectomy detectable serum PSA level precedes clinical evidence of disease progression by years, rare patients (2.3% in our series) in whom recurrent disease is characterized by marked histological dedifferentiation will remain negative for PSA.

摘要

相似文献

1
The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies.
J Urol. 1995 Dec;154(6):2128-31.
2
Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy.对于前列腺癌根治术后前列腺特异性抗原检测不到的男性,直肠指检和影像学检查并无必要。
J Urol. 1999 Oct;162(4):1337-40.
3
Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.对于根治性前列腺切除术后前列腺特异性抗原检测不到的男性患者,在常规随访中不再需要进行直肠指检:随访的意义
Eur Urol. 2005 Dec;48(6):906-10. doi: 10.1016/j.eururo.2005.07.006. Epub 2005 Aug 2.
4
Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.放疗后局部复发性前列腺癌挽救性根治性前列腺切除术的长期肿瘤学结果。
Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):448-53. doi: 10.1016/j.ijrobp.2004.09.049.
5
Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.采用超灵敏化学发光前列腺特异性抗原检测法早期发现复发性前列腺癌。
Urology. 1997 Oct;50(4):573-9. doi: 10.1016/S0090-4295(97)00251-3.
6
Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.前列腺癌根治术后生化及临床复发的挽救性放疗
Cancer J Sci Am. 1998 Sep-Oct;4(5):324-30.
7
Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.基于前列腺癌根治术后早期前列腺特异性抗原复发结果预测长期前列腺特异性抗原结局的准确性。
J Urol. 2001 Dec;166(6):2198-201.
8
Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.灵敏的前列腺特异性抗原检测可识别无疾病间隔期长的男性,并在根治性前列腺切除术后2年内区分侵袭性与惰性癌症复发。
J Urol. 1997 Apr;157(4):1322-8.
9
Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.接受根治性前列腺切除术后未能达到前列腺特异性抗原水平不可检测的患者疾病进展的自然史。
Cancer. 2004 Dec 1;101(11):2549-56. doi: 10.1002/cncr.20637.
10
Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.术前前列腺特异性抗原(PSA)水平与耻骨后根治性前列腺切除术后生化进展间隔时间显著相关。
Urology. 2004 Oct;64(4):723-8. doi: 10.1016/j.urology.2004.05.019.

引用本文的文献

1
Early Detection of Secondary Bladder Urothelial Carcinoma and Disseminated Bone Metastases with Normal Prostate-Specific Antigen Level after Pelvic Salvage Radiotherapy in Prostate Cancer.前列腺癌盆腔挽救性放疗后前列腺特异性抗原水平正常时继发性膀胱尿路上皮癌和播散性骨转移的早期检测
Life (Basel). 2023 May 25;13(6):1249. doi: 10.3390/life13061249.
2
Diagnostic performance of F-fluciclovine PET/CT in prostate cancer patients with rising PSA level ≤ 0.5 ng/ml after multiple treatment failures.多次治疗失败后 PSA 水平升高≤0.5 ng/ml 的前列腺癌患者中 F-氟代脱氧胸苷 PET/CT 的诊断性能
Am J Nucl Med Mol Imaging. 2021 Apr 15;11(2):87-98. eCollection 2021.
3
Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study.
基于人群的研究:前列腺癌患者 PSA 水平<4ng/ml 时的肿瘤特征、治疗方法和生存结果。
BMC Cancer. 2020 Apr 22;20(1):340. doi: 10.1186/s12885-020-06827-z.
4
Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.局部消融放疗挽救性治疗前列腺特异性抗原水平低或检测不到的去势抵抗性前列腺癌孤立性复发:一例报告
Oncol Lett. 2016 Jan;11(1):713-716. doi: 10.3892/ol.2015.3940. Epub 2015 Nov 18.
5
Focal therapy in prostate cancer: the current situation.前列腺癌的聚焦治疗:现状
Ecancermedicalscience. 2014 Jun 10;8:435. doi: 10.3332/ecancer.2014.435. eCollection 2014.
6
Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen.尽管血清前列腺特异性抗原水平极低,但前列腺癌仍进展。
Korean J Urol. 2010 May;51(5):358-61. doi: 10.4111/kju.2010.51.5.358. Epub 2010 May 19.
7
Prostate mechanical imaging: 3-D image composition and feature calculations.前列腺机械成像:三维图像合成与特征计算。
IEEE Trans Med Imaging. 2006 Oct;25(10):1329-40. doi: 10.1109/tmi.2006.880667.
8
Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.临床局限性前列腺癌根治性治疗后前列腺特异性抗原生化复发男性的评估与治疗
Rev Urol. 2001 Spring;3(2):72-84.
9
Regulation of the expression of the prostate-specific antigen by claudin-7.紧密连接蛋白7对前列腺特异性抗原表达的调控
J Membr Biol. 2003 Aug 1;194(3):187-97. doi: 10.1007/s00232-003-2038-4.
10
What does prostate-specific antigen recurrence mean?前列腺特异性抗原复发是什么意思?
Curr Urol Rep. 2000 May;1(1):28-35. doi: 10.1007/s11934-000-0032-2.